PROBIAL DERM

PROBIAL DERM® has been specifically developed to address dermatological allergic diseases, leveraging the clinically and immunologically proven efficacy of Ligilactobacillus salivarius LS01 in Atopic Dermatitis (AD), combined with Bifidobacterium breve BR03, a strain targeting proinflammatory responses [1-4]. This blend has demonstrated the ability to inhibit both E. coli and S. aureus, induce substantial secretion of IL-10 by human PBMCs in subjects with allergic asthma, and down-regulate the secretion of TGF-β, IL-13, and IL-17 in asthmatic subjects [5-7]. These actions contribute to the rebalancing of the Th1/Th2 ratio, improvement of allergic symptoms, and limitation of the proinflammatory response, while also aiding in maintaining tolerance to external antigens; all factors that are instrumental in ameliorating incidence and progression of AD.

The efficacy of PROBIAL DERM® has been evaluated in clinical studies across three different skin conditions: 1) scalp rosacea with low dose doxycycline (case study) [9]; 2) refractory chronic spontaneous urticaria (CSU) [10]; and 3) two studies on AD, one involving adults and the other focusing on babies and children with mild/moderate AD [7,8].

In adults with AD, a 3-month treatment with PROBIAL DERM® [7]:

• Significantly improved SCORAD score and Dermatology Life Quality Index (DLQI).

• Reduced microbial translocation (decreased LPS plasma concentration).

• Decreased immune activation, improved Th1/Th2 ratio, and Thelper cells Th17/Treg ratio.

• All these changes persisted after a 2-month suspension and were not observed in the placebo group.

In pediatric patients with mild/moderate AD, 3 months of supplementation with PROBIAL DERM® led to clinical improvement in AD (as evidenced by SCORAD score) and a reduction in the number of AD relapses, which was sustained even after 2 months from the end of the administration [8].

In a case of intermittent scalp rosacea with a 2-year history, 8 weeks of PROBIAL DERM® supplementation as an add-on to doxycycline treatment significantly improved cutaneous and ocular manifestations [9]. Notably, crusting and pustules completely disappeared, leaving only mild erythema. Doxycycline was suspended, and PROBIAL DERM® administration continued, with no signs of relapse or flare-up detected after 6 months of follow-up.

Additionally, the clinical efficacy and safety of PROBIAL DERM® intake in patients with CSU, who remained symptomatic despite concomitant H1-antihistamine therapy, was assessed [10]. An 8-week treatment with PROBIAL DERM® reduced disease activity and improved patients’ DLQI.